Cybin Inc (CYBN)

[psyched]

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

- Marks first ever trial to evaluate deuterated DMT in humans –

- Based on preclinical studies CYB004 demonstrated superior bioavailability compared to IV DMT which may support less invasive dosing methods -

- CYB004 is a patented proprietary molecule protected through 2041 -

https://ir.cybin.com/investors/news/news-details/2023/Cybin-Announces-Approval-of-First-in-Human-Dosing-of-its-Proprietary-DMT-Molecule-CYB004/default.aspx